Survodutide not linked to higher cardiovascular risk in phase 3 obesity trial
In a phase 3 cardiovascular safety trial of adults with obesity at increased risk, survodutide was non-inferior to placebo for major cardiovascular events, but caused far more gastrointestinal adverse events.

At a glance
- The primary composite endpoint occurred in 136 (3.7%) of 3671 survodutide participants and 76 (4.1%) of 1836 placebo participants (HR 0.89, 95% CI 0.67-1.18), meeting the non-inferiority margin of 1.65.
- Nausea and vomiting were much more frequent with survodutide, and gastrointestinal adverse events led to stopping treatment in 19.3% (3.6 mg) and 20.8% (6.0 mg) versus 1.9% with placebo.
- This was a safety trial. It does not show that survodutide protects the heart.
Key result
Survodutide was non-inferior to placebo for major cardiovascular events (HR 0.89).
Composite of CV death, stroke, MI, revascularisation, or heart failure
HR 0.89 (95% CI 0.67 to 1.18)
Survodutide vs placebo
The study
SYNCHRONIZE-CVOT was a global, phase 3, randomised, double-blind, placebo-controlled, event-driven cardiovascular safety trial. It was published in the Lancet and funded by Boehringer Ingelheim. It ran at 524 clinical sites in 34 countries.
Survodutide is a dual agonist of the glucagon receptor and the GLP-1 receptor. Adults aged 18 years or older with a BMI of 27 kg/m2 or greater were eligible. They also needed established cardiovascular disease, or at least two obesity complications or cardiovascular risk factors. People with chronic kidney disease could join if their BMI was 30 kg/m2 or greater.
Participants were randomly assigned 1:1:1 to once-weekly subcutaneous survodutide (up-titrated to 3.6 mg or 6.0 mg) or placebo. The primary endpoint was a composite of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event. The test was for non-inferiority of pooled survodutide versus placebo, with a margin of 1.65 for the upper limit of the 95% CI of the hazard ratio.
What they found
Of 5530 people randomly assigned, 5507 were treated. Of these, 1836 received survodutide 3.6 mg, 1835 received 6.0 mg and 1836 received placebo. In all, 2194 (39.8%) were female and 4332 (78.7%) were White. Median time in study was 22.0 months (IQR 20.1-23.7). Between 56.0% and 59.0% of each group stayed on treatment until study closeout.
The primary endpoint occurred in 136 (3.7%) of 3671 participants in the pooled survodutide group and in 76 (4.1%) of 1836 in the placebo group. The hazard ratio was 0.89 (95% CI 0.67-1.18). The upper limit of the CI was below the pre-set margin of 1.65, so survodutide was non-inferior to placebo (p<0.0001 for non-inferiority).
Adverse events occurred in 93.0% (3.6 mg), 93.1% (6.0 mg) and 85.6% (placebo). Gastrointestinal events were more frequent with survodutide:
- Nausea: 48.0% (3.6 mg) and 49.0% (6.0 mg) versus 12.1% with placebo.
- Vomiting: 31.7% (3.6 mg) and 34.0% (6.0 mg) versus 4.8% with placebo.
- Gastrointestinal events leading to discontinuation: 19.3% (3.6 mg) and 20.8% (6.0 mg) versus 1.9% with placebo.
Serious adverse events occurred in 22.5% (3.6 mg), 20.8% (6.0 mg) and 23.9% (placebo). Fatal adverse events occurred in 0.9%, 0.9% and 0.6%. They were mainly due to cardiac disorders (0.3%, 0.4% and 0.3%).
How much weight to give it
This is a large, randomised, double-blind phase 3 trial, which is a strong design for a safety question. The authors conclude that survodutide was not associated with increased cardiovascular risk and call the data reassuring. That reading fits the results.
The trial was built to show non-inferiority, not benefit. The point estimate of the hazard ratio was 0.89, but the CI includes 1. The data do not show that survodutide reduces cardiovascular events.
The primary analysis counted events regardless of early stopping of treatment. This matters because not all participants stayed on treatment to the end. The median time in study was 22.0 months, so longer-term safety is not covered. The abstract does not report results for the individual components of the composite endpoint, results in subgroups such as people with kidney disease, or weight outcomes. It also does not report how many participants were from India. Most participants were White.
For your clinic
This trial gives cardiovascular safety information. It does not support any change in practice by itself. The abstract does not say whether survodutide is available for use.
If drugs of this class reach practice, gastrointestinal tolerability looks like the main practical issue. In this trial, 19.3% and 20.8% of participants in the two survodutide groups stopped treatment because of gastrointestinal adverse events. Clinicians should read the full paper for the endpoint components, subgroup results, and the adverse event definitions before drawing conclusions for patients with established cardiovascular disease or kidney disease. Guidance from guideline bodies should also be checked as it appears.
Source
Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bozkurt B, le Roux CW, Wharton S et al.. Lancet (London, England). 9 November 2026
Cite this report: Diabesity Rounds. Survodutide not linked to higher cardiovascular risk in phase 3 obesity trial. 2026. doi:10.5281/zenodo.24236971
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on obesity medicine
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
- Trevogrumab reduced lean mass loss on semaglutide in phase 2 trialRandomised trial · 13 November 2026
- Resistance exercise reduced lean mass loss in adults on tirzepatide in a 40-week trialRandomised trial · 11 November 2026
- Retatrutide eased knee osteoarthritis pain more than placebo in two phase 3 trialsRandomised trial · 10 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.